

Hassane M Zarour

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8390065/hassane-m-zarour-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

1,735
citations

15
h-index

29
g-index

29
ext. papers

2,520
ext. citations

10.1
avg, IF

5.45
L-index

#	Paper	IF	Citations
22	Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.. <i>Nature Medicine</i> , 2022 ,	50.5	19
21	Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. <i>Science</i> , 2021 , 371, 595-602	33.3	211
20	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>OncotImmunology</i> , 2021 , 10, 1898105	7.2	2
19	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5520-5533	12.9	40
18	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. <i>Methods in Molecular Biology</i> , 2020 , 2055, 23-60	1.4	5
17	Targeting novel inhibitory receptors in cancer immunotherapy. <i>Seminars in Immunology</i> , 2020 , 49, 101436	0.7	3
16	TIGIT in cancer immunotherapy 2020 , 8,		129
15	IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. <i>Cancer Immunology Research</i> , 2019 , 7, 1258-1266	12.5	29
14	Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9572-9572	2.2	5
13	Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9579-9579	2.2	1
12	Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15175-e15175	2.2	
11	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800632	2.2	33
10	Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3054-3054	2.2	16
9	The microbiome: a basis for novel immunomodulation in mice and men. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 535-536	0.6	
8	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 1845-55	12.9	172
7	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9	27.4	666
6	Reversing T-cell Dysfunction and Exhaustion in Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1856-64	12.9	216

- 5 IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. *Cancer Research*, **2015**, 75, 1635-44 10.1 97
- 4 Immunotherapy in lung cancer. *Translational Lung Cancer Research*, **2014**, 3, 2-14 4.4 24
- 3 Cancer immunotherapy: Progress and challenges in the clinical setting. *European Journal of Immunology*, **2011**, 41, 1510-5 6.1 23
- 2 The cancer-germline antigen TRAG-3 stimulates Th1-type, Toll-like receptor 8-negative antigen-specific CD4+ regulatory T cells. *FASEB Journal*, **2008**, 22, 1079.19 0.9
- 1 Upregulation of PD-1 expression on tumor antigen-specific CD8+ T cells in patients with advanced melanoma is associated with reversible immune dysfunction. *FASEB Journal*, **2008**, 22, 1077.21 0.9